Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

New Cell Line

A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation

Abstract

We present the establishment of a natural killer (NK) leukemia cell line, designated KHYG-1, from the blood of a patient with aggressive NK leukemia, which both possessed the same p53 point mutation. The immunophenotype of the primary leukemia cells was CD2+, surface CD3, cytoplasmic CD3ε+, CD7+, CD8αα+, CD16+, CD56+, CD57+ and HLA-DR+. A new cell line (KHYG-1) was established by culturing peripheral leukemia cells with 100 units of recombinant interleukin (IL)-2. The KHYG-1 cells showed LGL morphology with a large nucleus, coarse chromatin, conspicuous nucleoli, and abundant basophilic cytoplasm with many azurophilic granules. The immunophenotype of KHYG-1 cells was CD1, CD2+, surface CD3, cytoplasmic CD3ε+, CD7+, CD8αα+, CD16, CD25, CD33+, CD34, CD56+, CD57, CD122+, CD132+, and TdT. Southern blot analysis of these cells revealed a normal germline configuration for the β, δ, and γ chains of the T cell receptor and the immunoglobulin heavy-chain genes. Moreover, the KHYG-1 cells displayed NK cell activity and IL-2-dependent proliferation in vitro, suggesting that they are of NK cell origin. Epstein–Barr virus (EBV) DNA was not detected in KHYG-1 cells by Southern blot analysis with a terminal repeat probe from an EBV genome. A point mutation in exon 7 of the p53 gene was detected in the KHYG-1 cells by PCR/SSCP analysis, and direct sequencing revealed the conversion of C to T at nucleotide 877 in codon 248. The primary leukemia cells also carried the same point mutation. Although the precise role of the p53 point mutation in leukemogenesis remains to be clarified, the establishment of an NK leukemia cell line with a p53 point mutation could be valuable in the study of leukemogenesis.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Loughran TP . Clonal diseases of large granular lymphocytes Blood 1993 82: 1–14

    PubMed  Google Scholar 

  2. Loughran TP, Starkebaum G . Large granular lymphocyte leukemia Medicine 1987 66: 397–405

    Article  PubMed  Google Scholar 

  3. Semenzato G, Pandolfi F, Chisesi T, DeRossi G, Pizzolo G, Zambello R, Trentin L, Agostini C, Dini E, Vespignani M, Cafaro A, Pasqualetti D, Giubellono C, Migone N, Foa R . The lympho-proliferative disease of granular lymphocytes Cancer 1987 60: 2971–2978

    CAS  Article  PubMed  Google Scholar 

  4. Fernandez LA, Pope B, Lee C, Zayed E . Aggressive natural killer cell leukemia in an adult and establishment of an NK cell line Blood 1986 67: 925–930

    CAS  PubMed  Google Scholar 

  5. Koizumi S, Seki H, Tachinami T, Taniguchi M, Matsuda A, Taga K, Nakarai T, Kato E, Taniguchi N, Nakamura H . Malignant clonal expansion of large granular lymphocytes with a Leu-11+, Leu-7 surface phenotype: in vitro responsiveness of malignant cells to recombinant human interleukin 2 Blood 1986 68: 1065–1073

    CAS  PubMed  Google Scholar 

  6. Sheridan W, Winton EF, Chan WC, Gordon DS, Vogler WR, Phillips C, Bongiovanni KF, Waldmann TA . Leukemia of non-T lineage natural killer cells Blood 1988 72: 1701–1707

    CAS  PubMed  Google Scholar 

  7. Kawa-Ha K, Ishihara S, Ninomiya T, Yagi K, Hara J, Murayama F, Tawa A, Hirai K . CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein–Barr viral DNA J Clin Invest 1989 84: 51–55

    CAS  Article  PubMed Central  PubMed  Google Scholar 

  8. Imamura N, Kusunoki Y, Kawa-Ha K, Yunuma K, Hara J, Oda K, Abe K, Dohy H, Inada T, Kajihara H, Kuramoto A . Aggressive natural killer cell leukemia/lymphoma: report of four cases and review of the literature Br J Haematol 1990 75: 49–59

    CAS  Article  PubMed  Google Scholar 

  9. Hart DNJ, Baker BW, Ingkis MJ, Nimmo JC, Starling GC, Deacon E, Rowe M, Beard MEJ . Epstein-Barr viral DNA in acute large granular lymphocytes (natural killer) leukemic cells Blood 1992 79: 2116–2123

    CAS  PubMed  Google Scholar 

  10. Jaffe ES . Classification of natural killer (NK) cell and NK-like T-cell malignancies Blood 1996 87: 1207–1210

    CAS  PubMed  Google Scholar 

  11. Gentile TC, Uner AH, Hutchinson RE, Wright J, Ben-Ezre J, Russel EC, Loughran TP . CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia Blood 1994 84: 2315–2321

    CAS  PubMed  Google Scholar 

  12. Macon WR, Williams ME, Greer JP, Hammer RD, Glick AD, Collins RD, Cousar JP . Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes Blood 1996 87: 1474–1483

    CAS  PubMed  Google Scholar 

  13. Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH . Identification of a common T/natural killer cell progenitor in human fetal thymus J Exp Med 1994 180: 569–576

    CAS  Article  PubMed  Google Scholar 

  14. Ichinohasama R, Endoh K, Ishizawa K, Okuda M, Kameoka J, Meguro K, Myers J, Kadin ME, Mori S, Sawai T . Thymic lymphoblastic lymphoma of committed natural killer cell precursor origin Cancer 1996 77: 2592–2603

    CAS  Article  PubMed  Google Scholar 

  15. Suzuki R, Yamamoto K, Seto M, Kagami Y, Ogura M, Yatabe Y, Suchi T, Kodera Y, Morishima Y, Takahashi T, Saito H, Ueda R, Nakamura S . CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity Blood 1997 90: 2417–2428

    CAS  PubMed  Google Scholar 

  16. Hartwell L . Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells Cell 1992 71: 543–546

    CAS  Article  PubMed  Google Scholar 

  17. Preudhomme C, Fenaux P . The clinical significance of mutations of the p53 tumor suppressor gene in haematological malignancies Br J Haematol 1997 98: 502–511

    CAS  Article  PubMed  Google Scholar 

  18. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Wattel E, Fenaux P . Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations Leukemia 1995 9: 370–381

    CAS  PubMed  Google Scholar 

  19. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T . Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma New Engl J Med 1997 337: 529–534

    CAS  Article  PubMed  Google Scholar 

  20. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen D, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP . Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood Blood 1993 82: 3163–3169

    CAS  PubMed  Google Scholar 

  21. Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffler HP . Mutations of the p53 gene in adult T-cell leukemia Blood 1992 79: 477–480

    CAS  PubMed  Google Scholar 

  22. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT . p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy Blood 1993 81: 128–135

    CAS  PubMed  Google Scholar 

  23. Homma T, Suzuki K, Kudo Y, Inagawa M, Mizuno S, Yamaguchi K, Tagawa M . Preparation and characterization of monoclonal antibodies against human myeloperoxidase Arch Biochem Biophys 1989 273: 189–196

    CAS  Article  PubMed  Google Scholar 

  24. Almasri NM, Iturraspe JA, Benson NA, Chen MG, Braylan RC . Flow cytometric analysis of terminal deoxynucleotidyl transferase Am J Clin Pathol 1991 95: 376–380

    CAS  Article  PubMed  Google Scholar 

  25. Gudelj L, Deniz G, Rukavina D, Johnson PM, Christmas SE . Expression of functional molecules by human CD3-decidual granular leucocyte clones Immunology 1996 87: 609–615

    CAS  Article  PubMed Central  PubMed  Google Scholar 

  26. Lichtenfels R, Biddison WE, Schultz H, Vogt AB, Martin R . CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity J Immunol Meth 1994 172: 227–239

    CAS  Article  Google Scholar 

  27. Neri A, Fracchiolla NS, Roscetti E, Garatti S, Trecca D, Bolentini A, Perletti L, Baldini L, Maiolo AT, Berti E . Molecular analysis of cutaneous B- and T-cell lymphomas Blood 1995 86: 3160–3172

    CAS  PubMed  Google Scholar 

  28. Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M . Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer Oncogene 1998 15: 2469–2477

    Article  Google Scholar 

  29. Kobayashi S, Iwata T, Saito M, Iwasaki R, Matsumoto H, Naritaka S, Kono Y, Hayashi Y . Mutations of the Btk gene in 12 unrelated families with X-linked agammaglobulinemia in Japan Hum Genet 1996 97: 424–430

    CAS  PubMed  Google Scholar 

  30. Prussin C, Foster B . TCR Vα24 and Vβ11 coexpression defines a human NKT cell analogue containing a unique Th0 subpopulation J Immunol 1997 159: 5862–5870

    CAS  PubMed  Google Scholar 

  31. Robertson MJ, Ritz J . Biology and clinical relevance of human natural killer cells Blood 1990 76: 2421–2438

    CAS  PubMed  Google Scholar 

  32. Hollstein M, Sidransky D, Vogelstein B, Harris CC . p53 mutations in human cancers Science 1991 253: 49–53

    CAS  Article  PubMed  Google Scholar 

  33. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH . Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome Nature 1990 348: 747–749

    CAS  Article  PubMed  Google Scholar 

  34. Nakamura S, Suchi T, Koshikawa T, Kitoh K, Koike K, Komatsu H, Iida S, Kagami Y, Ogura M, Katoh E, Kurita S, Suzuki H, Kobayashi Y, Yamabe H, Hirabayashi N, Ueda R, Takahashi T . Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract Am J Surg Pathol 1995 19: 284–296

    CAS  Article  PubMed  Google Scholar 

  35. Yoneda N, Tatsumi E, Teshigawara K, Nagata S, Nakano T, Kishimoto Y, Kawano S, Kimura T, Yasunaga K, Yamaguchi N . Lineage determination of CD7+ CD5− CD2− and CD7+ CD5+ CD2− lymphoblasts: studies on phenotype, genotype, and gene expression of myeloperoxidase, CD3ε, and CD3δ Am J Hematol 1994 45: 310–320

    CAS  Article  PubMed  Google Scholar 

  36. Michalovitz D, Halevy O, Oren M . p53 mutations. Gains or losses? J Cell Biochem 1991 45: 22–29

    CAS  Article  PubMed  Google Scholar 

  37. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinnzler KW, Vogelstein B . Oncogenic forms of p53 inhibit p53-regulated gene expression Science 1992 256: 827–830

    CAS  Article  PubMed  Google Scholar 

  38. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H . Frequent mutations in the p53 gene in human myeloid leukemia cell lines Blood 1992 79: 2378–2383

    CAS  PubMed  Google Scholar 

  39. Drexler HG, Fombonne S, Matsuo Y, Hu Z-B, Hamaguchi H, Uphoff CC . P53 alterations in human leukemia–lymphoma cell lines: in vitro artifact or prerequisite for cell immortalization? Leukemia 2000 14: 198–206

    CAS  Article  PubMed  Google Scholar 

  40. Karlhofer FM, Orihuela MM, Yokoyama WM . Ly-49-independent natural killer (NK) cell specificity revealed by NK cell clones derived from p53-deficient mice J Exp Med 1995 181: 1785–1795

    CAS  Article  PubMed  Google Scholar 

  41. Gong JH, Maki G, Klingemann HG . Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells Leukemia 1994 8: 652–658

    CAS  PubMed  Google Scholar 

  42. Ross E, Caligiuri MA . Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response Blood 1997 89: 910–918

    CAS  PubMed  Google Scholar 

  43. Stanbrige FJ . Identifying tumor suppressor genes in human colorectal cancer Science 1990 247: 12–13

    Article  Google Scholar 

  44. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F . Mutations of the p53 gene in lymphoid leukemia Blood 1991 77: 1153–1156

    CAS  PubMed  Google Scholar 

  45. Rolley N, Butcher S, Milner J . Specific DNA binding by different classes of human p53 mutants Oncogene 1995 11: 763–770

    CAS  PubMed  Google Scholar 

  46. Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, Weidauer H, Bosch FX . TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer Oncogene 1998 16: 1671–1679

    CAS  Article  PubMed  Google Scholar 

  47. Huang C, Kohno N, Inufusa H, Kodama K, Taki T, Miyake M . Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53 Am J Pathol 1999 155: 955–965

    CAS  Article  PubMed Central  PubMed  Google Scholar 

  48. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M, Uchiyama T, Maeda M . TCGF (IL-2)-receptor inducing factors: regulation of IL-2 receptors on a natural killer-like cell line (YT cells) J Immunol 1985 134: 1623–1630

    CAS  PubMed  Google Scholar 

  49. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J . Characterization of a cell line, NKL, derived from an agressive human natural killer cell leukemia Exp Hematol 1996 24: 406–415

    CAS  PubMed  Google Scholar 

  50. Tsuchiyama J, Yoshino T, Mori M, Kondoh E, Oka T, Akagi T, Hiraki A, Nakayama H, Shibuya A, Ma Y, Kawabata T, Okada S, Harada M . Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein–Barr virus infection Blood 1998 91: 1374–1383

    Google Scholar 

  51. Kagami Y, Nakamura S, Suzuki R, Iida S, Yatabe Y, Okada Y, Kobayashi T, Tsurumi T, Seto M, Ogura M . Establishment of an IL-2-dependent cell line derived from ‘nasal-type NK/T-cell lymphoma of CD2+, sCD3, CD3ɛ+, CD56+ phenotype and associated with the Epstein–Barr virus Br J Haematol 1998 103: 669–677

    CAS  Article  PubMed  Google Scholar 

  52. Drexler HG, Matsuo Y . Guidelines for the characterization and publication of human malignant hematopoietic cell lines Leukemia 1999 13: 835–842

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank Drs S Yamamori and H Matsumoto (Mitsubishi Kagaku Bio-Clinical Labs, Tokyo) for DNA sequencing; and Drs S Inoue and O Yoneda (Osaka Dental University) for proliferation assays. We thank the laboratory staff of SRL, Inc. for providing technical support. We also thank Drs E Tatsumi (Kobe University, Kobe, Japan), K Kita (Mie Medical School, Mie, Japan) and K Oshimi (Juntendo University School of Medicine, Tokyo, Japan) for their valuable comments.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yagita, M., Huang, C., Umehara, H. et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14, 922–930 (2000). https://doi.org/10.1038/sj.leu.2401769

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401769

Keywords

  • cell line
  • NK cell leukemia
  • p53
  • point mutation

Further reading

Search

Quick links